Hematological Oncology SCIE

国际简称：HEMATOL ONCOL 参考译名：血液肿瘤学

主要研究方向：血液学-医学非预警期刊审稿周期： 12周，或约稿

《血液肿瘤学》(Hematological Oncology)是一本由John Wiley and Sons Ltd出版的以血液学-医学为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。

4区中科院分区
Q2 JCR分区
93 年发文量
3.3 IF影响因子
未开放 是否OA
42 H-index
1983 创刊年份
Quarterly 出版周期
English 出版语言

Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:

-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders

-Diagnostic investigations, including imaging and laboratory assays

-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases

-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies

-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.

Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.

[ 查看全部 ]

投稿咨询加急咨询

Hematological Oncology期刊信息

ISSN：0278-0232
出版语言：English
是否OA：未开放
E-ISSN：1099-1069
出版地区：ENGLAND
是否预警：否
出版商：John Wiley and Sons Ltd
出版周期：Quarterly
创刊时间：1983
开源占比：0.1672
Gold OA文章占比：30.61%
OA被引用占比：0.1165...
出版国人文章占比：0.09
出版撤稿占比：0
研究类文章占比：65.59%

Hematological Oncology CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

4.2

0.82

0.717

学科类别	分区	排名	百分位
大类：Medicine 小类：Hematology	Q2	65 / 137	52%
大类：Medicine 小类：Oncology	Q2	197 / 404	51%
大类：Medicine 小类：Cancer Research	Q3	146 / 230	36%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Hematological Oncology中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	HEMATOLOGY 血液学 ONCOLOGY 肿瘤学	4区 4区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	HEMATOLOGY 血液学 ONCOLOGY 肿瘤学	4区 4区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	HEMATOLOGY 血液学 ONCOLOGY 肿瘤学	4区 4区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	HEMATOLOGY 血液学 ONCOLOGY 肿瘤学	3区 3区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	HEMATOLOGY 血液学 ONCOLOGY 肿瘤学	4区 4区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	4区	HEMATOLOGY 血液学 ONCOLOGY 肿瘤学	4区 4区

Hematological Oncology JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：HEMATOLOGY	SCIE	Q2	30 / 97	69.6%
学科：ONCOLOGY	SCIE	Q2	118 / 322	63.5%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：HEMATOLOGY	SCIE	Q3	49 / 97	50%
学科：ONCOLOGY	SCIE	Q3	212 / 322	34.32%

Hematological Oncology历年数据统计

影响因子

中科院分区

Hematological Oncology中国学者发文选摘

1、Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system
Author: Li, Xingying; Yu, Hui; Fu, Xiaorui; Zhang, Lei; Li, Xin; Li, Ling; Wang, Xinhua; Sun, Zhenchang; Zhang, Xudong; Li, Zhaoming; Wu, Jingjing; Chang, Yu; Yan, Jiaqin; Zhou, Zhiyuan; Nan, Feifei; Wu, Xiaolong; Tian, Li; Zhang, Mingzhi

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 267-274. DOI: 10.1002/hon.2894
2、Primary treatment and recent survival trends in patients with primary diffuse large B-cell lymphoma of central nervous system, 1995-2016: A population-based SEER analysis
Author: Chen, Cui; Sun, Peng; Sun, Xiao-Qing; Chen, Shao-Yong; Yang, Hang; Wang, Yu; Li, Zhi-Ming

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 248-256. DOI: 10.1002/hon.2918
3、Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis
Author: Lang, Mingxiao; Feng, Youqin; Meng, Xiangrui; Zhao, Jing; Song, Zheng; Qian, Zhengzi; Qiu, Lihua; Zhou, Shiyong; Liu, Xianming; Li, Lanfang; Yang, Haiyan; Song, Yuqin; Li, Wei; Zhang, Huilai

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 239-247. DOI: 10.1002/hon.2928
4、Review on natural killer/T-cell lymphoma
Author: He, Xiaohua; Gao, Yan; Li, Zhiming; Huang, Huiqiang

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 221-229. DOI: 10.1002/hon.2944
5、Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma
Author: Song, Wenting; Chen, Zhan; Shi, Cunzhen; Gao, Yuyang; Feng, Xiaoyan; Li, Hongwen; Li, Zhaoming; Zhang, Mingzhi

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 257-266. DOI: 10.1002/hon.2954
6、TAFRO syndrome with fatigue and abdominal distension as the first symptom: A case report
Author: Zhou, Bai; Tang, Chao; Chen, Guiyang; Jiang, Tiebin; Shi, Xiao; Wang, Fen

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 285-290. DOI: 10.1002/hon.2962
7、Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden
Author: Mu, Juan; Deng, Haobin; Lyu, Cuicui; Yuan, Jijun; Li, Qing; Wang, Jia; Jiang, Yanyu; Deng, Qi; Shen, Jichun

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 275-284. DOI: 10.1002/hon.2981
8、Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma
Author: Li, Xiao; Liu, Mengke; Shi, Qing; Fang, Ying; Fu, Di; Shen, Zhi-xiang; Yi, Hongmei; Wang, Li; Zhao, Weili

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 230-238. DOI: 10.1002/hon.2993